Find and Pitch Jounalists, Get Your Story Covered

Tags: carboplatin atezolizumab breast cancer obesity paclitaxel

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Scottish medicines consortium approves CAR T-cell therapy for blood cancer - 7 days ago Poolbeg’s cytokine release syndrome drug shows potential - 10 months ago
2	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Sequencing in Advanced Urothelial Carcinoma - 17 days ago Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma - 11 months ago KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer - 11 months ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: A drug may cause problems with chemotherapies in cancer patients with obesity. Many doctors are in the dark - 21 days ago
4	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Is New Standard of Care for High-Risk Early-Stage TNBC - 2 months ago Phase 3 Study Supports Pembrolizumab Plus Lenvatinib as Standard of Care in Patients With Advanced Endometrial Cancer Who Received Prior Platinum Therapy - about 1 year ago
5	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 2 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma - 2 months ago Novel PARP1 Inhibitor Shows Promise in Breast Cancer - 7 months ago Chemotherapy/ICI Combos Falter as Second-Line Treatment for Gastric Cancer - 8 months ago Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - 8 months ago First-Line Nivolumab Plus Chemo Approved for Bladder Cancer - 9 months ago Novel Therapy Promising for Radiation-Induced Oral Mucositis - 9 months ago Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results - 9 months ago New First-Line Option for Pancreatic Cancer Approved - 9 months ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - 10 months ago Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone - 10 months ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - 11 months ago FDA OKs First Drug for Nasopharyngeal Carcinoma - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - about 1 year ago Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer - about 1 year ago Pembrolizumab Wins FDA Approval in Operable Lung Cancer - about 1 year ago
6	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Grants Orphan Drug Designation to PT217 for Neuroendocrine Carcinoma - 3 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 8 months ago Pembrolizumab, Chemoradiotherapy Meet Overall Survival Endpoint for Cervical Cancer - 8 months ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - 9 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 10 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - 11 months ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - about 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - about 1 year ago
7	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 4 months ago
8	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 5 months ago Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC - 8 months ago Novel Chemotherapy Method Could Decrease Lung Cancer Tumor Size - 9 months ago FDA Approves Irinotecan Liposome for Metastatic Pancreatic Adenocarcinoma - 9 months ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - about 1 year ago
9	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 5 months ago Non-Covalent BTK Inhibitor Approved for CLL - 12 months ago New Oral Drug Approved for Metastatic Colorectal Cancer - about 1 year ago
10	Ryan Haumschild, PharmD, MS, MBA Pharmacy Times Director of Pharmacy. Editorial Board member. Atlanta, Georgia pharmacyhealthcareeditorial workadvisory	Alternative Treatments for eBC and mBC - 5 months ago

Journalists covering carboplatin